comparemela.com

Latest Breaking News On - For investor - Page 3 : comparemela.com

Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced that screening is underway in Study SRP-9003-301. Also known as EMERGENE, Study 9003-301 is a.

United statesLouise rodino klapacTrademark officeSarepta therapeutics incExchange commissionSarepta therapeuticsPrecision genetic medicine engineFor investorUnited states patentAnnual report

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue

– Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023 – Preliminary ELEVIDYS net product revenue is expected to be $131.3 million for the fourth quarter.

San franciscoUnited statesDoug ingramSarepta therapeutics incSarepta therapeuticsHealthcare conferenceSerious liver injurySafety informationPrecision genetic medicine engineFor investorQuarterly report

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported preliminary fourth quarter and full-year 2023 net product revenue and cash on hand as of December 31, 2023, as part of its presentation today at.

San franciscoUnited statesDoug ingramSarepta therapeutics incTherapeutics reportsFourth quarterHealthcare conferenceSerious liver injurySafety informationPrecision genetic medicine engineFor investorQuarterly report

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, granted equity awards on December 29, 2023 that were previously approved by the Compensation Committee of its.

Sarepta therapeutics incCompensation committeeSarepta therapeuticsCommencement incentive planNasdaq listing ruleGrant datePrecision genetic medicine engineFor investor

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomIan estepanCompensation committeeSarepta therapeutics incCommencement incentive planNasdaq listing ruleGrant datePrecision genetic medicine engineFor investorSarepta therapeutics

vimarsana © 2020. All Rights Reserved.